Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Sponsors
Center for Bioequivalence Studies and Clinical Research,Beijing Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years male and female; 2. Confirmed Coronavirus infection by real time RT-PCR; 3. Mild cases of Coronavirus having main symptoms with minimum 2 grade (as mentioned in 7.1.2); 4. The subject has signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with moderate or critical Coronavirus infection confirmed by real time RT-PCR (rRT-PCR); cases meeting any of the following criteria: (1) Lung lesions; (2) Respiratory failure and requiring mechanical ventilation; (3) Shock; (4) With other organ failure that requires ICU cares; 2. Severe primary health conditions associated with cardiovascular, cerebrovascular, pulmonary, hepatic, renal, endocrine and hematological diseases, hematopoietic system (above grade II of cardiac function; ALT & AST are 1.5 times higher than the normal value; Creatinine above the upper limit of normal value) and mental illness or serious diseases affecting their survival, such as cancer or AIDS; 3. With severe cardiopulmonary dysfunction, cardiopulmonary insufficiency; 4. Subjects, who took other antiviral, antibacterial, cough relieving, expectorant and antiasthmatic drugs within 3 days prior to the visit (including ß2 receptor agonists, anticholinergic agents, theophylline drugs, glucocorticoids, expectorant and Chinese Medicine.); 5. Allergic individuals and those who are known to be allergic to experimental drugs; 6. Pregnant women, lactating women or fertile women who are ready to conceive in 3 months; 7. Subject, who has participated in the past 1 month in another clinical study; 8. Subjects who are not suitable for the clinical trial based on investigators judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change (improvement) in clinical signs and symptoms;Negative test time for SARS-CoV2 on RT-PCR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Observation of body temperature: The onset time of fever and the complete time of defervescence.;Quality of Life Criterion;Chang in white blood cells, C-reactive protein and ferritin.;Change in radiographic findings of the lungs.; | — |
Countries
Pakistan
Contacts
Public ContactProf. Dr M. Raza Shah T.I./Liu Qing Quan
Outcome results
None listed